LifeScan launches telemedicine-enabled glucose meter
MILPITAS, Calif. — LifeScan on Monday introduced the new OneTouch VerioSync Meter, which uses Bluetooth technology to wirelessly send blood sugar test results to devices using the OneTouch Reveal mobile app.
From the OneTouch Reveal mobile app’s summary screen, users can see their key information at a glance, including color-coded bar graphs showing the percentage of results within, above and below their personalized target ranges and 14-day averages of blood sugar readings. Individuals can also access a color-coded electronic logbook that automatically displays test results over a two-week period, as well as other features that allow them to enter and view information about carbohydrates consumed, physical activity and medication.
And with the OneTouch Reveal mobile app’s data sharing feature, key information can be shared with healthcare professionals, caregivers or family members via text or email.
“When you consider how many of us rely on our smartphones on a daily basis, managing chronic illnesses such as diabetes is a promising area for mobile health applications,” Jeremy Pettus, of the UCSD Department of Endocrinology, said. “It’s exciting to see true wireless communication brought to blood glucose monitoring. By helping patients to easily access, understand and share their blood sugar data via their iPhones, a system like the OneTouch VerioSync can help lead to better self-management and more productive conversations with their healthcare professionals."
The meter has an introductory promotional price of $19.99 and is available at the OneTouch online store and will also be available at http://www.Walgreens.com, http://www.CVS.com, http://www.RiteAid.com and http://www.Walmart.com.
CDC: Flu prevalence remains high
ATLANTA — According to this week’s FluView report, overall flu activity continued to be high across the nation, with activity continuing to spread from state to state, the Centers for Disease Control and Prevention reported Friday. Thirty-five states are now experiencing widespread activity, and 20 states are reporting high levels of influenza-like illness.
For the week ended Jan. 4, the proportion of people seeing their healthcare provider for ILI decreased, but remains above the national baseline. "The apparent decrease this week is likely due to differences in care-seeking, testing and reporting practices over the holidays, rather than an actual decline in flu activity," the CDC noted.
Twenty states experienced high ILI activity, the same number as in the previous week. Seven states and New York City experienced moderate ILI activity, while 11 states experienced low ILI activity, and 12 states experienced minimal ILI activity.
To date, influenza A (H1N1) viruses have predominated. This is the same H1N1 virus that emerged in 2009 to cause a pandemic, CDC noted. H1N1 viruses have continued to circulate among people since that time, but this is the first season that the virus has circulated at high levels since the pandemic.
The predominant flu strains in circulation are well matched to the Northern Hemisphere quadrivalent and trivalent vaccines for the 2013-2014 season.
The neuraminidase inhibitors Tamiflu (oseltamivir) and Relenza (zanamivir) are currently the only recommended influenza antiviral drugs. While the vast majority of the viruses that have been tested are sensitive to oseltamivir and zanamivir, three additional 2009 H1N1 viruses proved resistant to oseltamivir during the week ended Jan. 4. So far this season 13 (1.2%) 2009 H1N1 viruses have shown resistance to oseltamivir. No viruses have shown resistance to zanamivir.
As in recent past seasons, high levels of resistance to the adamantanes (Symmetrel (amantadine) and Flumadine (rimantadine)) continue to persist among 2009 H1N1 and influenza A (H3N2) viruses. Adamantanes are not effective against influenza B viruses. Adamantanes are not recommended for use against influenza this season, the CDC noted.
Real Health Labs launches Prostate Complete Once Per Day
SAN DIEGO — Real Health Labs recently launched Prostate Complete Once Per Day, a pharmaceutical-grade supplement combination, the company stated.
In addition to zinc, selenium and vitamin E, Prostate Complete Once Per Day is formulated with a standardized saw palmetto extract, lycopene, a standardized curcumin extract, resveratrol and a pomegranate concentrate.
"Our newest prostate product is an all-natural, comprehensive formulation that includes clinically studied amounts of all of the standardized extracts that have been shown to support overall prostate health," the company stated. "More and more doctors are recommending the use of saw palmetto extract, the powerful antioxidant lycopene, pumpkin seed extract and selenium for prostate health."
A 30-day supply retails for a suggested $16.99.